Age related macular degeneration (AMD) is a blinding disease of the elderly affecting nearly one in three individuals over the age of 75. Central vision is lost in AMD, severely impairing the ability to read, watch television, or drive. The epicenter of AMD is the retinal pigment epithelium (RPE), a single layer of cells in the retina adjacent to the photoreceptor cells. A recent breakthrough in AMD research showed that this disease is caused in about 50% of cases by the innate immune system (complement system) inappropriately attacking RPE cells. Specifically, AMD results when regulators of the complement system, which normally protect the RPE, are weakened by mutations. This sickens and later kills the RPE, causing secondary degeneration of photoreceptors in the central retina (macula).
The goal of this proposal is to develop a strategy for transplanting stem-cell derived RPE cells into the eyes of patients with AMD. In the past, transplantation of RPE cells from postmortem donors yielded encouraging initial therapeutic effects that subsequently failed due to immune rejection. Current stem-cell technology offers the opportunity to avoid this complication. We plan to generate functional RPE cells from stem cells of the ciliary margin zone (CMZ) in the eye, or pluripotent stem cells induced from skin fibroblasts (iPS cells) taken from the same AMD patient who will later receive the induced RPE cells as a transplant.
The study of inherited blindness has benefited greatly from mouse genetic models, where new potential therapies can be tested and developed. One aim of this proposal is to produce RPE cells from mouse and human CMZ- and iPS-cell precursors. To establish that these cells are functional, we will test for two hallmarks of a fully differentiated RPE: (i) the ability to convert vitamin A into visual chromophore for photoreceptor-opsin pigments, and (ii) the ability to phagocytose photoreceptor outer-segments. In a later aim we will transplant these induced RPE cells into the eyes of two genetic “knockout” mice that lack the ability to synthesize visual chromophore. We will test for rescue of the biochemical defects, and correction of the blindness in these mutant mice. In another experiment, we will add to the induced RPE cells a gene that protects from inappropriate complement activation. These cells will be transplanted into the eyes of two other knockout mouse-models of AMD that exhibit abnormal activation of the complement system. We will study these mice to establish correction of the immune defect. Finally, we will test the safety of CMZ- and iPS-derived RPE cells by transplanting them into immune-deficient mice to confirm no tumor formation. At the end of the grant period, we expect to have a new and well-tested stem-cell based transplantation strategy that will be ready for phase-one clinical trials in AMD patients.
This proposal is to develop a stem-cell based transplantation approach for treating age-related macular degeneration (AMD). AMD is a severe and common disease of the elderly that causes central blindness. The prevalence of AMD increases with advancing age. By 75 years, approximately one in three individuals have some degree of visual loss due to AMD. Thus AMD is significantly more prevalent than Alzheimer disease. Patients with AMD lose the ability to drive, read, watch TV, and recognize faces. With advancing visual impairment, AMD patients lose the ability to care for themselves and others. Thus, AMD imposes a large social and economic burden on our society. As the population in California ages, this burden is expected to increase. The stem-cell based transplantation strategy in this proposal offers the real potential of slowing or arresting the progression of blindness in AMD patients. This alone would represent an important benefit to the people of California.
Further, the project would advance innovative technology in stem cell therapy. This technology has application to other neurodegenerative diseases. The project will train new stem-cell researchers in California. As the project enters the clinical phase, it will engage new scientists and physicians and attract funding by the federal government. Further, the opportunity to treat a hugely prevalent disease like AMD will undoubtedly attract biotechnology investment in California.
This stem-cell based transplantation approach to treat a major disease like AMD is well-aligned with the broad mission of CIRM and the objectives of the Early Translational Research Award program.
The broad goal of this project is to develop a stem-cell derived replacement for RPE cells in the eye that die in patients with age-related macular degeneration (AMD). Since RPE cells are often genetically defective in AMD, we will correct this defect in the stem-cell derived RPE cells before transplanting them into patients. These transplanted cells will express specific proteins that will protect them from being attacked by the innate immune system. During the first year of funding we made excellent progress toward this goal. We learned how to generate RPE cells from mouse and human stem cells of various sources. We prepared all the DNA constructs that will be required to protect the transplanted RPE cells from attack by the innate immune system. We also developed a new approach for injecting RPE cells into the correct part of the mouse eye (subretinal space) without damaging other parts of the retina. We are enthusiastic to continue our work on this exciting project.
The broad goal of this project is to develop a stem-cell derived replacement for retinal pigment epithelial (RPE) cells in the eye, which die in patients with age-related macular degeneration (AMD). Since RPE cells are often genetically defective in AMD, we will correct this defect in the stem-cell derived RPE cells before transplanting them into patients. These transplanted cells will express specific proteins that will protect them from being attacked by the innate immune system. During our second year of funding, we transplanted human stem-cell derived RPE cells into the eyes of mice that are blind due to a genetic defect in the rpe65 gene. We showed that the human cells integrated into the RPE layer of these mice. Further, we demonstrated that the transplanted cells partially rescued the blindness in rpe65 / mice. We also generated and tested the recombinant viruses that will protect RPE cells from attack by the innate immune system. We are on schedule to complete the planned studies for this project during the final year of funding.
This project is to develop a new treatment for age-related macular degeneration (AMD) based on transplantation of retinal pigment epithelial (RPE) cells into the subretinal space of a patient’s eyes. These RPE cells are induced from stem cells collected from the same patient, to avoid the problem of immune rejection. AMD is primarily an inflammatory disorder caused by inappropriate attack of RPE cells by the complement system. Accordingly, negative regulators of complement activation will be expressed in the stem-cell derived RPE cells by viral transduction. We explored two sources of stem cells that can be collected from a patient: embryonic stem cells and induced pluripotent stem (iPS) cells from skin fibroblasts. We successfully programed these stem cells into fully functional RPE cells. Our team has extensive experience with the biochemistry and cell biology of the RPE. We used “knockout” mouse models with mutations in RPE genes to test the efficiency of RPE-cell transplantation. Next, we planned to test the strategy of protecting RPE cells from complement attack by over-expressing complement negative-regulatory factors. We tested the long-term viability of induced RPE cells, and rule-out tumorgenicity by transplanting these cells into the eyes of severe-combined immunodeficient mice.